로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > Envelope protein > ENN-V5243

pHERV-W Envelope protein, His Tag

Order Now

  • Synonym
    Envelope protein,Env polyprotein,Envelope glycoprotein,env
  • Source
    pHERV-W Envelope protein, His Tag(ENN-V5243) is expressed from human 293 cells (HEK293). It contains AA Ser 30 - Lys 316 (Accession # AAK18189.1).
    Predicted N-terminus: His
  • Molecular Characterization
    Envelope protein Structure

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 33.9 kDa. The protein migrates as 48-58 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Envelope protein SDS-PAGE

pHERV-W Envelope protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Background
    Dengue virus envelope (E) glycoprotein is a class II fusion protein mediating viral attachment and entry. Organized as dimers on the virion surface, it binds host receptors and, upon endosomal acidification, undergoes dramatic conformational rearrangements to drive membrane fusion. Structurally, E comprises three domains (DI, DII, DIII), with DIII responsible for receptor recognition. Highly immunogenic, E elicits neutralizing antibodies and is the principal target for vaccine design and therapeutic antibody development, as inhibiting its fusogenic transition blocks dengue virus infection.
  • Clinical and Translational Updates

Comments (0)

Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop